

William P. Deni, Jr.
Charles H. Chevalier
J. Brugh Lower
GIBBONS P.C.
One Gateway Center
Newark, New Jersey 07102
Tel: (973) 596-4500
Fax: (973) 596-0545

*Attorneys for Plaintiffs
Merck Sharp & Dohme B.V.
and Organon USA Inc.*

**UNITED STATES DISTRICT COURT
DISTRICT OF NEW JERSEY**

MERCK SHARP & DOHME B.V. and
ORGANON USA INC.,

Plaintiffs,

v.

ASPIRO PHARMA LIMITED,

Defendant.

Civil Action No. 20-3112

Document Electronically Filed

COMPLAINT FOR PATENT INFRINGEMENT

Plaintiffs Merck Sharp & Dohme B.V. (“Merck B.V.”) and Organon USA Inc. (“Organon”) (together, “Merck”), by their attorneys, bring this complaint against Defendant Aspiro Pharma Limited (“Aspiro”), and hereby allege as follows:

NATURE OF THE ACTION

1. This is an action for patent infringement under the patent laws of the United States, 35 U.S.C. § 100, *et seq.*, including 35 U.S.C. § 271(e)(2), the Drug Price Competition and Patent Term Restoration Act of 1984, 21 U.S.C. § 355(j) (the “Hatch-Waxman Act”), and the Declaratory Judgment Act, 28 U.S.C. §§ 2201 and 2202, that arises out of Aspiro’s submission of

an Abbreviated New Drug Application (“ANDA”) to the U.S. Food and Drug Administration (“FDA”) seeking approval to commercially manufacture, use, offer for sale, sell, and/or import all strengths of a purported generic version of Bridion[®] (sugammadex) Injection prior to the expiration of U.S. Patent Nos. RE44,733 (“the ’733 patent”) and 6,949,527 (“the ’527 patent”).

PARTIES

2. Plaintiff Merck Sharp & Dohme B.V. (“Merck B.V.”) is a corporation organized and existing under the laws of the Netherlands with its principal place of business at Waarderweg 39, Haarlem, Netherlands 2031 BN. Merck B.V. is an indirect, wholly owned subsidiary of Merck & Co., Inc., a New Jersey corporation, which has its principal place of business at 2000 Galloping Hill Road, Kenilworth, New Jersey 07033.

3. Plaintiff Organon USA Inc. (“Organon”) is a corporation organized and existing under the laws of the State of New Jersey with its principal place of business at One Merck Drive, Whitehouse Station, New Jersey 08889. Organon is a wholly owned subsidiary of Merck & Co., Inc.

4. On information and belief, Defendant Aspiro Pharma Limited (“Aspiro”) is a corporation organized and existing under the laws of India, with a place of business at House No. 8-3-166/7/1, 3rd Floor, Erragadda Hyderabad, Telangana, 500018 India. On information and belief, Aspiro is in the business of, among other things, manufacturing, promoting, marketing, selling, offering for sale, using, distributing, and importing into the United States, generic versions of branded pharmaceutical drugs for the U.S. market, itself or through its U.S. agents.

5. By a letter dated February 18, 2020 (“Aspiro Notice Letter”), Aspiro notified Merck that Aspiro had submitted to the FDA ANDA No. 214337 (“Aspiro’s ANDA”) for purported generic versions of sugammadex injection, 200 mg/2 mL and 500 mg/5 mL (“Aspiro ANDA Products”), seeking FDA approval to engage in the commercial manufacture, use, sale,

offer for sale, and/or importation of the Aspiro ANDA Products in or into the United States, including New Jersey, prior to the expiration of the '733 and '527 patents.

JURISDICTION AND VENUE

6. Merck incorporates each of the preceding paragraphs 1–5 as if fully set forth herein.

7. This is a civil action for patent infringement arising under the patent laws of the United States, 35 U.S.C. § 100, *et seq.*, including 35 U.S.C. § 271, for infringement of the asserted patents. This Court has jurisdiction over the subject matter of this action pursuant to 28 U.S.C. §§ 1331, 1338(a), 2201, and 2202.

8. Aspiro is subject to personal jurisdiction in New Jersey because, among other things, Aspiro itself, and through its U.S. agents, has purposely availed itself of the benefits and protections of New Jersey's laws such that it should reasonably anticipate being sued in this Court. On information and belief, Aspiro itself, and through its U.S. agents, develops, manufactures, imports, markets, distributes, uses, offers to sell, and/or sells generic drugs.

9. Aspiro has committed an act of infringement in this judicial district by filing ANDA No. 214337 with the intent to make, use, sell, offer for sale, and/or import the Aspiro ANDA Products in or into this judicial district, prior to the expiration of the '733 and '527 patents.

10. Aspiro has taken the costly, significant step of applying to the FDA for approval to engage in future activities, including the marketing of the Aspiro ANDA Products, that will be purposefully directed at New Jersey and elsewhere in the United States.

11. On information and belief, if Aspiro's ANDA is approved, Aspiro will manufacture, market, promote, sell, offer for sale, import, use and/or distribute the Aspiro ANDA Products within the United States, including in New Jersey. On information and belief, the Aspiro ANDA Products will be prescribed by physicians practicing in New Jersey, dispensed by

pharmacies located within New Jersey, and used by patients in New Jersey. Each of these activities would have a substantial effect within New Jersey and would constitute infringement of the '733 and '527 patents in the event that the Aspiro ANDA Products are approved before the '733 and '527 patents expire.

12. Additionally, this Court has personal jurisdiction over Aspiro because the requirements of Federal Rule of Civil Procedure 4(k)(2)(A) are met as (a) Merck's claims arise under federal law; (b) Aspiro is a foreign defendant not subject to general personal jurisdiction in the courts of any state; and (c) Aspiro has sufficient contacts in the United States as a whole, including, but not limited to, by participating in the preparation and submission of Aspiro's ANDA, and/or Aspiro's future manufacturing and/or selling of the Aspiro ANDA Products throughout the United States, including in this judicial district, such that this Court's exercise of jurisdiction over Aspiro satisfies due process.

13. Venue is proper in this Court as to Aspiro because Aspiro is a foreign entity who may be sued in any judicial district, including in the District of New Jersey. 28 U.S.C. § 1391(c)(3); *see also* 28 U.S.C. § 1400(b).

THE PATENTS-IN-SUIT

14. Merck B.V. is the owner and assignee of the '733 patent, entitled "6-Mercapto-Cyclodextrin Derivatives: Reversal Agents For Drug-Induced Neuromuscular Block" (attached as Exhibit A). Merck B.V. has the right to enforce the '733 patent.

15. The '733 patent was duly and legally issued on January 28, 2014. The '733 patent was a reissue of U.S. Patent No. 6,670,340, which was duly and legally issued on December 30, 2003.

16. The '733 patent includes claims that recite 6-per-deoxy-6-per-(2-carboxyethyl)thio- γ -cyclodextrin, compositions containing 6-per-deoxy-6-per-(2-

carboxyethyl)thio- γ -cyclodextrin, methods of using 6-per-deoxy-6-per-(2-carboxyethyl)thio- γ -cyclodextrin, and kits containing 6-per-deoxy-6-per-(2-carboxyethyl)thio- γ -cyclodextrin.

17. 6-Per-deoxy-6-per-(2-carboxyethyl)thio- γ -cyclodextrin is also referred to as sugammadex.

18. The FDA's Approved Drug Products with Therapeutic Equivalence Evaluations ("Orange Book") currently lists the expiration of the '733 patent as January 27, 2021. On February 4, 2020, the United States Patent and Trademark Office ("PTO") issued a Notice Of Final Determination on the patent term extension ("PTE") application for the '733 patent, wherein the PTO determined that the '733 patent is eligible for 5 years of PTE (attached as Exhibit B). Therefore, after the PTE certificate is issued, the expiration of the '733 patent will be January 27, 2026.

19. Merck B.V. is the owner and assignee of the '527 patent, entitled "6-Mercapto-Cyclodextrin Derivatives: Reversal Agents For Drug-Induced Neuromuscular Block" (attached as Exhibit D). Merck B.V. has the right to enforce the '527 patent.

20. The '527 patent was duly and legally issued on September 27, 2005.

21. The '527 patent includes claims that recite methods of using 6-per-deoxy-6-per-(2-carboxyethyl)thio- γ -cyclodextrin and kits containing 6-per-deoxy-6-per-(2-carboxyethyl)thio- γ -cyclodextrin.

22. The FDA's Orange Book currently lists the expiration of the '527 patent as January 27, 2021.

THE BRIDION® DRUG PRODUCT

23. Organon is the holder of New Drug Application ("NDA") No. 022225, under which the FDA approved the commercial marketing of Bridion® (sugammadex) Injection ("Bridion®") on December 15, 2015, under Section 505(a) of the Federal Food, Drug, and

Cosmetic Act (“FDCA”), 21 U.S.C. § 355(a). Bridion[®] is approved for the reversal of neuromuscular blockade induced by rocuronium bromide and vecuronium bromide in adults undergoing surgery. Bridion[®] is distributed in the United States by Merck Sharp and Dohme Corp., a wholly owned subsidiary of Merck & Co., Inc., in 200 mg/2 mL and 500 mg/5 mL strengths in a single-dose vial for bolus injection. A true and correct copy of the current prescribing information for Bridion[®] is attached as Exhibit C.

24. Bridion[®] is a first-in-class drug that works differently than prior agents used for the reversal of neuromuscular blockade. The active ingredient in Bridion[®], sugammadex, is a modified cyclodextrin that acts by directly encapsulating, binding, and inactivating agents used by healthcare providers to induce neuromuscular blockade in patients undergoing surgery, e.g., rocuronium or vecuronium, to reverse their effects. After intravenous injection, Bridion[®] distributes through plasma and binds to such neuromuscular blocking agents (“NMBAs”) to form a complex. This process reduces the amount of NMBA available to bind to nicotinic cholinergic receptors in the neuromuscular junction, resulting in the reversal of neuromuscular blockade.

25. By this mechanism, Bridion[®] also avoids several of the side effects associated with prior reversal agents, such as acetylcholinesterase inhibitors. Traditional reversal agents are co-administered with other agents to manage these side effects, but the co-administered agents can cause a number of additional side effects. Moreover, Bridion[®] is capable of reversing the complete and prolonged block of neuromuscular function (known as “profound block”) that can occur with the administration of NMBAs. Further, intravenous administration of sugammadex results in more rapid recovery from moderate or deep neuromuscular blockade in patients undergoing surgery who received rocuronium or vecuronium, as compared to neostigmine or succinylcholine. Because of at least these unique features, Bridion[®] has been viewed as a

significant advance in the field of anesthesiology.

26. Bridion[®], as well as methods of using Bridion[®], are covered by one or more claims of the '733 and '527 patents. The '733 and '527 patents have been listed in connection with NDA No. 022225 in the FDA's Orange Book.

DEFENDANT'S ANDA AND NOTICE OF PARAGRAPH IV CERTIFICATION

27. On information and belief, Aspiro has submitted or caused the submission of Aspiro's ANDA to the FDA under 21 U.S.C. § 355(j), to obtain approval to engage in the commercial manufacture, use, offer to sell, or sale within the United States or importation into the United States of the Aspiro ANDA Products, as a purported generic version of Bridion[®], prior to the expiration of the '733 and '527 patents.

28. On information and belief, the FDA has not yet approved Aspiro's ANDA.

29. In the Aspiro Notice Letter, Aspiro notified Merck of the submission of Aspiro's ANDA to the FDA. The purpose of this submission was to obtain approval under the FDCA to engage in the commercial manufacture, use, offer for sale, sale, and/or importation of the Aspiro ANDA Products prior to the expiration of the '733 and '527 patents.

30. In the Aspiro Notice Letter, Aspiro acknowledged that the Reference Listed Drug for Aspiro's ANDA is Bridion[®]. Bridion[®] is indicated for the reversal of neuromuscular blockade induced by rocuronium bromide and vecuronium bromide in adults undergoing surgery.

31. In the Aspiro Notice Letter, Aspiro also notified Merck that, as part of its ANDA, Aspiro had filed a purported Paragraph IV Certification pursuant to 21 U.S.C. § 355(j)(2)(A)(vii)(IV), with respect to the '733 and '527 patents.

32. On information and belief, Aspiro submitted its ANDA to the FDA containing certifications pursuant to 21 U.S.C. § 355(j)(2)(A)(vii)(IV) asserting that the '733 and '527 patents are invalid, unenforceable, and/or will not be infringed by the manufacture, use, offer

for sale, sale, and/or importation of the Aspiro ANDA Products.

33. In the Aspiro Notice Letter, Aspiro stated that the Aspiro ANDA Products contain sugammadex as an active ingredient.

34. On information and belief, Aspiro prepared and submitted Aspiro's ANDA, and intends to further prosecute Aspiro's ANDA. On information and belief, if the FDA approves Aspiro's ANDA, Aspiro will manufacture, distribute, promote, market, offer for sale, or sell the Aspiro ANDA Products within the United States, or will import the Aspiro ANDA Products into the United States. On information and belief, if the FDA approves Aspiro's ANDA, Aspiro will actively induce or contribute to the manufacture, use, offer for sale, sale, or importation of the Aspiro ANDA Products in or into the United States.

35. Merck brings this action within forty-five days of receipt of the Aspiro Notice Letter. Accordingly, Merck is entitled to a stay of FDA approval pursuant to 21 U.S.C. § 355(j)(5)(B)(iii).

COUNT I – INFRINGEMENT OF THE '733 PATENT

36. Merck incorporates each of the preceding paragraphs 1–35 as if fully set forth herein.

37. The Aspiro ANDA Products, and the use of the Aspiro ANDA Products, are covered by one or more claims of the '733 patent, including at least claim 1 of the '733 patent, because claim 1 of the '733 patent encompasses the sugammadex utilized in the Aspiro ANDA Products.

38. In the Aspiro Notice Letter, Aspiro did not contest infringement of claims 1-5, 9, 11-14, 20 and 21 of the '733 patent.

39. Aspiro's submission of Aspiro's ANDA with a Paragraph IV Certification for the purpose of obtaining approval to engage in the commercial manufacture, use, offer for sale,

sale, and/or importation of the Aspiro ANDA Products in or into the United States before the expiration of the '733 patent is an act of infringement of the '733 patent under 35 U.S.C. § 271(e)(2)(A).

40. If approved by the FDA, Aspiro's commercial manufacture, use, importation, sale, and/or offer for sale of the Aspiro ANDA Products in or into the United States will directly infringe, contribute to the infringement of, and/or actively induce the infringement of one or more claims of the '733 patent under 35 U.S.C. § 271(a)-(c).

41. On information and belief, Aspiro will engage in the commercial manufacture, use, offer for sale, sale, marketing, distribution, and/or importation of the Aspiro ANDA Products in or into the United States immediately and imminently upon approval of Aspiro's ANDA.

42. The commercial manufacture, use, sale, offer for sale, or importation of the Aspiro ANDA Products in or into the United States would infringe one or more claims of the '733 patent.

43. On information and belief, the commercial manufacture, use, sale, offer for sale, or importation of the Aspiro ANDA Products in accordance with, and as directed by, its proposed product labeling would infringe one or more claims of the '733 patent.

44. On information and belief, upon FDA approval of Aspiro's ANDA, Aspiro will, through its own actions or through the actions of its agents, market and/or distribute the Aspiro ANDA Products to resellers, pharmacies, hospitals, clinics, healthcare professionals, and other end users. On information and belief, Aspiro will knowingly and intentionally accompany the Aspiro ANDA Products with a product label or product insert that will include instructions for using or administering the Aspiro ANDA Products, which are substantially similar to the

instructions in the prescribing information for Bridion[®], attached as Exhibit C, and which, if followed, will infringe the '733 patent. Accordingly, Aspiro will induce resellers, pharmacies, hospitals, clinics, healthcare professionals, and other end users of the Aspiro ANDA Products to directly infringe the '733 patent. On information and belief, Aspiro will encourage acts of direct infringement with knowledge of the '733 patent and knowledge that Aspiro is encouraging infringement.

45. On information and belief, Aspiro plans and intends to, and will, actively induce infringement of the '733 patent when Aspiro's ANDA is approved, and plans and intends to, and will, do so immediately and imminently upon approval. Aspiro's activities will be done with knowledge of the '733 patent and specific intent to infringe that patent.

46. On information and belief, Aspiro knows that the Aspiro ANDA Products and proposed labeling are especially made or adapted for use in infringing the '733 patent, that the Aspiro ANDA Products are not a staple article or commodity of commerce, and that the Aspiro ANDA Products and accompanying proposed labeling are not suitable for substantial noninfringing use. On information and belief, Aspiro plans and intends to, and will, contribute to infringement of the '733 patent immediately and imminently upon approval of Aspiro's ANDA.

47. Notwithstanding Aspiro's knowledge of the claims of the '733 patent, Aspiro has continued to assert its intent to manufacture, use, offer for sale, sell, distribute, and/or import the Aspiro ANDA Products with its product labeling in or into the United States following FDA approval of Aspiro's ANDA prior to the expiration of the '733 patent.

48. The foregoing actions by Aspiro constitute and/or will constitute direct infringement of the '733 patent; active inducement of infringement by others of the '733 patent; and contribution to the infringement by others of the '733 patent.

49. On information and belief, Aspiro filed Aspiro's ANDA with a Paragraph IV Certification without adequate justification for asserting that the '733 patent is invalid, unenforceable, and/or not infringed by the commercial manufacture, use, offer for sale, sale, or importation in or into the United States of the Aspiro ANDA Products. On information and belief, Aspiro has acted with full knowledge of the '733 patent and without a reasonable basis for believing that it would not be liable for direct infringement of the '733 patent; active inducement of infringement by others of the '733 patent; and/or contribution to the infringement by others of the '733 patent. On information and belief, the direct and indirect infringement by Aspiro of the '733 patent was and is willful. Aspiro's conduct renders this case "exceptional" under 35 U.S.C. § 285.

50. Merck will be substantially and irreparably damaged by infringement of the '733 patent. Unless Aspiro is enjoined from directly infringing the '733 patent, actively inducing infringement of the '733 patent, and contributing to the infringement of the '733 patent, Merck will suffer irreparable injury. Merck has no adequate remedy at law, and considering the balance of hardships between Merck and Aspiro, a remedy in equity is warranted. Further, the public interest would not be disserved by the entry of an injunction.

COUNT II – INFRINGEMENT OF THE '527 PATENT

51. Merck incorporates each of the preceding paragraphs 1–50 as if fully set forth herein.

52. The Aspiro ANDA Products, and the use of the Aspiro ANDA Products, are covered by one or more claims of the '527 patent, including at least claim 4 of the '527 patent, because claim 4 of the '527 patent recites a method of treatment with the sugammadex encompassed in the Aspiro ANDA Products.

53. In the Aspiro Notice Letter, Aspiro did not contest infringement of claims

4 and 5 of the '527 patent.

54. Aspiro's submission of Aspiro's ANDA with a Paragraph IV Certification for the purpose of obtaining approval to engage in the commercial manufacture, use, offer for sale, sale, and/or importation of the Aspiro ANDA Products in or into the United States before the expiration of the '527 patent is an act of infringement of the '527 patent under 35 U.S.C. § 271(e)(2)(A).

55. If approved by the FDA, Aspiro's commercial manufacture, use, importation, sale, and/or offer for sale of the Aspiro ANDA Products in or into the United States will directly infringe, contribute to the infringement of, and/or actively induce the infringement of one or more claims of the '527 patent under 35 U.S.C. § 271(a)-(c).

56. On information and belief, Aspiro will engage in the commercial manufacture, use, offer for sale, sale, marketing, distribution, and/or importation of the Aspiro ANDA Products in or into the United States immediately and imminently upon approval of Aspiro's ANDA.

57. The commercial manufacture, use, sale, offer for sale, or importation of the Aspiro ANDA Products in or into the United States would infringe one or more claims of the '527 patent.

58. On information and belief, the commercial manufacture, use, sale, offer for sale, or importation of the Aspiro ANDA Products in accordance with, and as directed by, its proposed product labeling would infringe one or more claims of the '527 patent.

59. On information and belief, upon FDA approval of Aspiro's ANDA, Aspiro will, through its own actions or through the actions of its agents, market and/or distribute the Aspiro ANDA Products to resellers, pharmacies, hospitals, clinics, healthcare professionals, and

other end users. On information and belief, Aspiro will knowingly and intentionally accompany the Aspiro ANDA Products with a product label or product insert that will include instructions for using or administering the Aspiro ANDA Products, which are substantially similar to the instructions in the prescribing information for Bridion[®], attached as Exhibit C, and which, if followed, will infringe the '527 patent. Accordingly, Aspiro will induce resellers, pharmacies, hospitals, clinics, healthcare professionals, and other end users of the Aspiro ANDA Products to directly infringe the '527 patent. On information and belief, Aspiro will encourage acts of direct infringement with knowledge of the '527 patent and knowledge that Aspiro is encouraging infringement.

60. On information and belief, Aspiro plans and intends to, and will, actively induce infringement of the '527 patent when Aspiro's ANDA is approved, and plans and intends to, and will, do so immediately and imminently upon approval. Aspiro's activities will be done with knowledge of the '527 patent and specific intent to infringe that patent.

61. On information and belief, Aspiro knows that the Aspiro ANDA Products and proposed labeling are especially made or adapted for use in infringing the '527 patent, that the Aspiro ANDA Products are not a staple article or commodity of commerce, and that the Aspiro ANDA Products and accompanying proposed labeling are not suitable for substantial noninfringing use. On information and belief, Aspiro plans and intends to, and will, contribute to infringement of the '527 patent immediately and imminently upon approval of Aspiro's ANDA.

62. Notwithstanding Aspiro's knowledge of the claims of the '527 patent, Aspiro has continued to assert its intent to manufacture, use, offer for sale, sell, distribute, and/or import the Aspiro ANDA Products with its product labeling in or into the United States following FDA approval of Aspiro's ANDA prior to the expiration of the '527 patent.

63. The foregoing actions by Aspiro constitute and/or will constitute direct infringement of the '527 patent; active inducement of infringement by others of the '527 patent; and contribution to the infringement by others of the '527 patent.

64. On information and belief, Aspiro filed Aspiro's ANDA with a Paragraph IV Certification without adequate justification for asserting that the '527 patent is invalid, unenforceable, and/or not infringed by the commercial manufacture, use, offer for sale, sale, or importation in or into the United States of the Aspiro ANDA Products. On information and belief, Aspiro has acted with full knowledge of the '527 patent and without a reasonable basis for believing that it would not be liable for direct infringement of the '527 patent; active inducement of infringement by others of the '527 patent; and/or contribution to the infringement by others of the '527 patent. On information and belief, the direct and indirect infringement by Aspiro of the '527 patent was and is willful. Aspiro's conduct renders this case "exceptional" under 35 U.S.C. § 285.

65. Merck will be substantially and irreparably damaged by infringement of the '527 patent. Unless Aspiro is enjoined from directly infringing the '527 patent, actively inducing infringement of the '527 patent, and contributing to the infringement of the '527 patent, Merck will suffer irreparable injury. Merck has no adequate remedy at law, and considering the balance of hardships between Merck and Aspiro, a remedy in equity is warranted. Further, the public interest would not be disserved by the entry of an injunction.

PRAYER FOR RELIEF

WHEREFORE, Merck requests the following relief:

- (a) A judgment that the '733 patent has been infringed under 35 U.S.C. § 271(e)(2) by Aspiro's submission to the FDA of Aspiro's ANDA;
- (b) A judgment, pursuant to 35 U.S.C. § 271(e)(4)(A), ordering that the effective date

of any FDA approval of the commercial manufacture, use, or sale of the Aspiro ANDA Products, or any other drug product that infringes or the use of which infringes the '733 patent, be not earlier than the expiration date of the '733 patent, inclusive of any extension(s) and additional period(s) of exclusivity;

(c) A preliminary and permanent injunction, pursuant to 35 U.S.C. §§ 271(e)(4)(B) and 283 and Rule 65, Fed. R. Civ. P., enjoining Aspiro, and all persons acting in concert with Aspiro, from the commercial manufacture, use, offer for sale, or sale in the United States, or importation into the United States of the Aspiro ANDA Products, or any other drug product covered by or whose use is covered by the '733 patent, prior to the expiration of the '733 patent, inclusive of any extension(s) and additional period(s) of exclusivity;

(d) A judgment declaring that the commercial manufacture, use, offer for sale, or sale in the United States, or importation into the United States of the Aspiro ANDA Products, or any other drug product that is covered by or whose use is covered by the '733 patent, prior to the expiration of the '733 patent, inclusive of any extension(s) and additional period(s) of exclusivity, will infringe, induce the infringement of, and contribute to the infringement by others of the '733 patent;

(e) A declaration that Aspiro's commercial manufacture, use, offer for sale, or sale in the United States, or importation into the United States, of the Aspiro ANDA Products, or inducing or contributing to such conduct, would constitute infringement of one or more claims of the '733 patent by Aspiro under one or more of 35 U.S.C. § 271(a), (b), and (c);

(f) An award of damages or other relief, pursuant to 35 U.S.C. § 271(e)(4)(C), if Aspiro engages in the commercial manufacture, use, offer for sale, or sale in the United States, or importation into the United States of the Aspiro ANDA Products, or any product that infringes the

'733 patent, or induces or contributes to such conduct, prior to the expiration of the '733 patent, inclusive of any extension(s) and additional period(s) of exclusivity;

(g) A judgment that Aspiro willfully and deliberately infringed the '733 patent;

(h) A judgment that the '527 patent has been infringed under 35 U.S.C. § 271(e)(2) by Aspiro's submission to the FDA of Aspiro's ANDA;

(i) A judgment, pursuant to 35 U.S.C. § 271(e)(4)(A), ordering that the effective date of any FDA approval of the commercial manufacture, use, or sale of the Aspiro ANDA Products, or any other drug product that infringes or the use of which infringes the '527 patent, be not earlier than the latest of the expiration date of the '527 patent, inclusive of any extension(s) and additional period(s) of exclusivity;

(j) A preliminary and permanent injunction, pursuant to 35 U.S.C. §§ 271(e)(4)(B) and 283 and Rule 65, Fed. R. Civ. P., enjoining Aspiro and all persons acting in concert with Aspiro, from the commercial manufacture, use, offer for sale, or sale in the United States, or importation into the United States of the Aspiro ANDA Products, or any other drug product covered by or whose use is covered by the '527 patent, prior to the expiration of the '527 patent, inclusive of any extension(s) and additional period(s) of exclusivity;

(k) A judgment declaring that the commercial manufacture, use, offer for sale, or sale in the United States, or importation into the United States of the Aspiro ANDA Products, or any other drug product that is covered by or whose use is covered by the '527 patent, prior to the expiration of the '527 patent, will infringe, induce the infringement of, and contribute to the infringement by others of the '527 patent;

(l) A declaration that Aspiro's commercial manufacture, use, offer for sale, or sale in the United States, or importation into the United States, of the Aspiro ANDA Products, or inducing

or contributing to such conduct, would constitute infringement of one or more claims of the '527 patent by Aspiro under one or more of 35 U.S.C. § 271(a), (b), and (c);

(m) An award of damages or other relief, pursuant to 35 U.S.C. § 271(e)(4)(C), if Aspiro engages in the commercial manufacture, use, offer for sale, or sale in the United States, or importation into the United States of the Aspiro ANDA Products, or any product that infringes the '527 patent, or induces or contributes to such conduct, prior to the expiration of the '527 patent, inclusive of any extension(s) and additional period(s) of exclusivity;

(n) A judgment that Aspiro willfully and deliberately infringed the '527 patent;

(o) A declaration that this is an exceptional case and an award of attorney's fees pursuant to 35 U.S.C. § 285;

(p) Costs and expenses in this action; and

(q) Such further and other relief as this Court may deem just and proper.

Dated: March 20, 2020
Newark, New Jersey

Of Counsel:

John J. Normile (*pro hac vice* to be submitted)
Sarah A. Geers
Lisamarie LoGiudice (*pro hac vice* to be submitted)
JONES DAY
250 Vesey Street
New York, NY 10281
(212) 326-3939

Andrea Weiss Jeffries (*pro hac vice* to be submitted)
JONES DAY
555 S. Flower Street
Los Angeles, CA 90071
(213) 243-2176

Anthony M. Insogna
JONES DAY
4655 Executive Drive, Suite 1500
San Diego, CA 92121-3134
(858) 314-1130

Jihong Lou (*pro hac vice* to be submitted)
JONES DAY
51 Louisiana Avenue, NW
Washington, DC 20001-2113
(202) 879-3631

Shayna Cook (*pro hac vice* to be submitted)
Alan Littmann (*pro hac vice* to be submitted)
Doug Winnard (*pro hac vice* to be submitted)
Lauren Abendshien (*pro hac vice* to be submitted)
**GOLDMAN ISMAIL TOMASELLI
BRENNAN & BAUM LLP**
200 S. Wacker Drive, 22nd Floor
Chicago, IL 60606
(312) 681-6000

Respectfully submitted,

s/ William P. Deni, Jr.
William P. Deni, Jr.
Charles H. Chevalier
J. Brugh Lower
GIBBONS P.C.
One Gateway Center
Newark, New Jersey 07102
Tel: (973) 596-4500
Fax: (973) 596-0545
wdeni@gibbonslaw.com
cchevalier@gibbonslaw.com
jlower@gibbonslaw.com

*Attorneys for Plaintiffs
Merck Sharp & Dohme B.V.
and Organon USA Inc.*